Intralipid ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	3

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03773237 (ClinicalTrials.gov)	December 31, 2018	12/11/2018	Intralipid Versus SMOFlipid in HPN Patients	Randomized Prospective Trial Comparing Intralipid Versus SMOFlipid in New HPN Patients.	Short Bowel Syndrome;Intestinal Fistula;Crohn Disease;Intestinal Obstruction	Dietary Supplement: SMOFLipid;Dietary Supplement: Intralipid	Mayo Clinic	NULL	Active, not recruiting	18 Years	75 Years	All	22	N/A	United States
2	NCT02349594 (ClinicalTrials.gov)	January 2014	16/1/2015	Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease	Modulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over Study	Crohn Disease	Drug: Omegaven 10%;Drug: Intralipid 20%	Radboud University	NULL	Completed	18 Years	70 Years	Both	6	Phase 4	Netherlands
3	EUCTR2013-001212-30-NL (EUCTR)	04/07/2013	18/06/2013	Immune modulation by parenteral Fish oil in patients with Crohn’s disease	Modulation of immune function by parenteral fish oil in patients with Crohn’s disease and high inherent Tumor Necrosis Factor-alfa production, a randomized, single blinded, cross-over study	Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Omegaven Trade Name: Intralipid 10%		NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands